References
- Pugliati M, Rosari G, Carton H, et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol 2006;13:700-22
- Sudstrom P, Svenningsson A, Nystrom L, et al. Clinical characteristics of multiple sclerosis in Vasterbotten County in northern Sweden. J Neurol Neurosurg Psychiatry 2004;75:711-16
- Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52
- Kobelt G, Berg J, Lindgren P, et al. Cost and quality of life in multiple sclerosis in Europe: method of assessment and analysis. Eur J Health Econ 2006;7(2 Suppl):5-13
- Patwardhan MB, Matchar DB, Samsa GP, et al. Cost of multiple sclerosis by level of disability: a review of literature. Mult Scler J 2005;11:232-9
- Sobocki P, Pugliati M, Lauer K, et al. Estimation of the costs of MS in Europe: extrapolations from a multinational cost study. Mult Scler 2007;13:1054-64
- Lublin FD, Baier M, Cutter G. Effects of relapses on development of residual deficit in multiple sclerosis. Neurology 2003;61:1528-32
- Kieseier BC, Stüve O. A critical appraisal of treatment decisions in multiple sclerosis – old versus new. Nature Rev Neurol 2011;7:255-62
- Cohen JA, Barkhof F, Comi G, et al; for the TRANSFORMS study group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. New Engl J Med 2010;362:402-15
- Comi G, O’Conner P, Montalban X, et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler 2010;16:197-207
- Portaccio E. Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis. Core Evidence 2010;6:13-21
- Gani R, Giovannoni G, Bates D, et al. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with rapidly evolving severe relapsing–remitting multiple sclerosis in the UK. Pharmacoeconomics 2008;26:617-27
- Chiao E, Meyer K. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis. Curr Med Res Opin 2009;25:1445-54
- O’Day K, Meyer K, Miller R, et al. Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis. J Med Econ 2011;14:617-27
- Naci H, Fleurette R, Birt J, et al. Economic burden of multiple sclerosis: a systematic review of the literature. Pharmacoeconomics 2010;28:363-79
- Novartis Pharma GmbH. Gilenya summary of product characteristics. European Medicines Agency. Nuremberg, Germany. 2011. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002202/WC500104528.pdf. Accessed March 9, 2012
- Biogen Idec Denmark Manufacturing ApS. Tysabri summary of product characteristics. European Medicines Agency. Hillerød, Denmark. 2011. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000603/WC500044686.pdf. Accessed March 9, 2012
- Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New Engl J Med 2006;354:899-910
- Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. New Engl J Med 2010;362:1-15
- Pricing database. Dental and Pharmaceutical Benefits Agency, TLV. http://www.tlv.se/beslut/sok/lakemedel/. 2011. Accessed March 9, 2012
- Hutchinson M, Kappos L, Calabresi PA, et al. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol 2009;256:405-15
- Devonshire V, Havrdova E, Radue EW, et al. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol 2012;11:420-8
- O’Brien JA, Ward AJ, Patrick AR, et al. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res 2003;3:17-28
- Goldberg LD, Edwards NC, Fincher C, et al. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing–remitting multiple sclerosis. J Manag Care Pharm 2009;15:543-55
- Lee S, Baxter DC, Roberts MS, Coleman CL. Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States. J Med Econ 2012;15:1088-96
- Agashivala N, Kim E. Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis. Clin Ther 2012;34:1583-90
- Bergvall N, Tambour M, Henriksson F, et al. Cost-minimization analysis of fingolimod compared with natalizumab for the treatment of relapsing-remitting multiple sclerosis in Sweden. J Med Econ 2013;16:349-57
- Kleinman NL, Beren IA, Rajagopalan K, et al. Medication adherence with disease modifying treatments for multiple sclerosis among US employees. J Med Econ 2010;13:633-40